Stock Markets May 11, 2026 08:57 AM

Inhibrx Posts Encouraging Phase 2 Results for INBRX-106 Combination; Shares Jump Pre-Market

Hexavalent OX40 agonist plus pembrolizumab shows higher confirmed response rate and immune activation signals in first-line PD-L1 positive HNSCC patients

By Caleb Monroe INBX

Inhibrx reported positive interim Phase 2 data from the HexAgon study, where INBRX-106 combined with pembrolizumab produced a 44.0% confirmed objective response rate versus 21.4% for pembrolizumab alone in treatment-naïve, PD-L1 positive metastatic or unresectable recurrent head and neck squamous cell carcinoma. The announcement preceded an 11.7% premarket rise in the company's shares.

Inhibrx Posts Encouraging Phase 2 Results for INBRX-106 Combination; Shares Jump Pre-Market
INBX

Key Points

  • INBRX-106 combined with pembrolizumab produced a 44.0% confirmed ORR versus 21.4% for pembrolizumab alone in the Phase 2 evaluable population.
  • Peripheral blood assays showed up to a 15-fold mean increase in CD8+ and CD4+ T-cell proliferation in the combination arm versus up to 2.5-fold with pembrolizumab alone, supporting a mechanistic rationale for the clinical responses.
  • The combination had a manageable safety profile with predominantly low-grade treatment-related adverse events and no treatment-related deaths reported.

Overview

Inhibrx Biosciences Inc shares rose 11.7% in pre-market trading on Monday after the company disclosed interim results from the Phase 2 portion of its HexAgon study. The data relate to INBRX-106, a hexavalent OX40 agonist, administered in combination with pembrolizumab and compared against pembrolizumab monotherapy in a first-line population.


Trial population and measured outcomes

The Phase 2 segment enrolled 68 patients overall. Randomization placed 33 patients in the INBRX-106 plus pembrolizumab arm and 35 patients in the pembrolizumab-only control arm. The evaluable cohort comprised 53 patients.

Within that evaluable population, 11 of 25 patients receiving the combination achieved a confirmed objective response, yielding a confirmed objective response rate (ORR) of 44.0% for the combination arm. By comparison, 6 of 28 patients in the control arm achieved a confirmed objective response, equivalent to a 21.4% ORR. The company reported this as a 22.6 percentage-point absolute increase in confirmed ORR for the combination versus pembrolizumab alone.

Three complete responses were documented in the combination arm; no complete responses occurred in the pembrolizumab monotherapy arm.


Mechanistic and safety findings

Peripheral blood analyses demonstrated mean increases in T-cell proliferation with the combination regimen. In patients treated with INBRX-106 plus pembrolizumab, mean proliferation of CD8+ and CD4+ T cells increased by up to 15-fold. By contrast, patients receiving pembrolizumab alone showed up to 2.5-fold mean increases. The company characterized these immune changes as providing mechanistic support for the clinical activity observed.

On safety, the combination displayed a manageable profile consistent with expectations for an immunotherapy combination. The most frequently reported treatment-related adverse events were rash, diarrhea, fatigue, and infusion-related reactions, with most events described as low-grade. No treatment-related deaths were reported in either arm of the Phase 2 portion.


Next steps and timing

Inhibrx indicated it expects progression-free survival data from the Phase 2 portion in the fourth quarter of 2026 and plans to initiate the Phase 3 portion during the third quarter of 2026.


Summary

The interim Phase 2 results show a higher confirmed objective response rate and evidence of amplified T-cell proliferation with INBRX-106 plus pembrolizumab versus pembrolizumab alone in first-line, treatment-naïve, PD-L1 positive metastatic or unresectable recurrent head and neck squamous cell carcinoma. The data coincided with an 11.7% pre-market increase in Inhibrx shares.

Risks

  • Interim nature of the Phase 2 results - final outcomes including progression-free survival are pending and expected in the fourth quarter of 2026, which could change the risk-benefit profile.
  • Relatively small evaluable sample size - the Phase 2 evaluable population comprised 53 patients, which limits precision and may affect generalizability of the response rates.
  • Safety and efficacy in broader populations remain to be confirmed - the Phase 3 portion, planned to begin in the third quarter of 2026, will be needed to validate these findings.

More from Stock Markets

S&P Moves Mexico’s Outlook to Negative, Citing Fiscal Strain and Tepid Growth May 12, 2026 Moody's Lowers Everforth Outlook to Negative Amid Elevated Leverage May 12, 2026 Moody's Moves Albemarle Outlook to Stable After Debt Cuts and Stronger Lithium Prices May 12, 2026 Moody's Keeps Garrett Motion Rating Steady, Moves Outlook to Positive May 12, 2026 S&P Lowers Embecta Rating After Sharp Revenue Drop and Market Share Loss May 12, 2026